CD19 and cancer: One approach that has been revisited recently is to redirect natural killer (NK) cells to the cancer cells using scFv antibodies targeting CD16a (FcγRIIIa) fused via a short linker to another scFv targeting receptors on the cancer cells (e.g., CD19), similar to a BiTE® format.